Biogen BIIB Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.42B-4.0% | $1.34B-17.8% | $1.61B-0.4% | $1.53B+32.2% | $1.48B+26.7% | ||
| $801.1M+13.0% | $779.9M+15.8% | $763.7M+21.4% | $744.3M+30.2% | $708.9M+33.8% | ||
| $293.8M-1.9% | $290.8M-0.1% | $306.3M+13.0% | $303.7M+16.6% | $299.4M+14.5% | ||
| $413M+283% | $361.6M+329% | $136.3M— | -$170.1M— | -$225.8M— | ||
| —— | -$102.7M+53.8% | -$132.6M— | -$162.5M— | -$192.4M— | ||
| $10.5M-92.2% | $64.7M-76.4% | $101.7M-66.5% | $113.5M— | $134.1M— | ||
| $228.4M— | $171.1M— | $76.1M— | —— | —— | ||
| —— | -$248M-38.8% | -$230.68M-51.3% | -$213.35M-68.9% | -$196.03M-95.8% | ||
| —— | —— | —— | —— | —— | ||
| -$1.01B-773% | -$958.1M-1,321% | -$747.7M-512% | -$448.5M-100.0% | $149.8M+141% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $2.59B+0.4% | $2.2B-23.3% | $2.45B+15.3% | $2.12B+18.7% | $2.58B+56.9% | ||
| $167.9M+15.9% | $153.8M+0.1% | $149.2M-16.9% | $138M-36.9% | $144.9M-43.5% | ||
| —— | —— | —— | —— | $0-100% | ||
| —— | —— | -$40.1M-101% | -$57.5M-101% | -$55.6M-101% | ||
| $21.6M-84.7% | $31.6M-84.7% | $42.3M-76.4% | $132M+35.4% | $141.1M+35.2% | ||
| -$42.9M-1,121% | -$42.9M-1,013% | -$19.9M-238% | $32M+137% | $4.2M-62.8% | ||
| —— | —— | —— | —— | $0— | ||
| -$1.53B-96.5% | -$1.37B-71.6% | -$158M+89.0% | -$1.3B+34.6% | -$780.5M+75.7% | ||
| —— | —— | —— | —— | —— | ||
| $291.2M+4,953% | $281.2M— | $142.5M+7,600% | -$4.7M-175% | -$6M+34.8% | ||
| -$322.7M-17.4% | -$301.9M+56.3% | -$164.9M— | -$41.3M— | -$274.8M— | ||
| $52.8M+613% | $105.1M+255% | $28.2M-48.4% | $70.6M+528% | -$10.3M— | ||
| —— | —— | $2.14B— | —— | —— | ||
| $297M+25.2% | $240.8M+4.7% | $210.3M-2.9% | $199.7M+20.5% | $237.3M+214% | ||
| —— | —— | —— | —— | —— | ||
| $27.1M-66.8% | $29.6M-71.0% | $47.5M-63.7% | $71.8M-45.6% | $81.7M-39.3% | ||
| —— | $52.9M— | $39.68M— | $26.45M— | $13.23M— | ||
| -$89.6M+36.4% | -$68.3M+57.2% | -$113.8M+21.4% | -$110.6M+27.6% | -$140.9M+0.9% | ||
| —— | $85M— | $63.75M— | $42.5M— | $21.25M— | ||
| -$42.9M-1,121% | -$42.9M-1,013% | -$19.9M-238% | $32M+137% | $4.2M-62.8% | ||
| —— | —— | —— | —— | $0— | ||
| $21.6M-84.7% | $31.6M-84.7% | $42.3M-76.4% | $132M+35.4% | $141.1M+35.2% | ||
| —— | $0-100% | $101.7M-79.7% | $203.4M-66.0% | $305.1M-56.0% | ||
| —— | —— | —— | —— | —— | ||
| $2.42B-0.6% | $2.05B-24.7% | $2.3B+15.2% | $1.98B+22.3% | $2.44B+69.0% | ||
| $2.42B-0.6% | $2.05B-24.7% | $2.3B+15.2% | $1.98B+22.3% | $2.44B+69.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Biogen generate?
- Biogen (BIIB) generated $2.6B in operating cash flow over the trailing twelve months.
- What is Biogen's free cash flow?
- After $167.9M of capital expenditures, Biogen's free cash flow was $2.4B over the trailing twelve months, down 0.6% year over year.
- Where does Biogen's cash flow data come from?
- Every line is extracted from Biogen's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
